leukemia/phosphatase

Lyen an sove nan clipboard la

Chwazi kalite sòt

10 rezilta yo

Magnetic Resonance Imaging:A Window to Anthracycline Toxicity

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a pilot study with a descriptive study design. Anthracycline induced late onset cardiotoxicity, defined in terms of abnormal findings on echocardiography, has been reported to occur in 57% of childhood cancer survivors. Serial monitoring of cardiac function by means of echocardiography

ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study Rationale 1. AML is a bone marrow based malignancy that is rapidly growing and rapidly fatal if left untreated. Despite therapeutic strategies for up to 70% of patients, 20% are primarily refractory and another 50% will relapse after first line therapy. Among these refractory and relapsed

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with PSC often have ongoing inflammation and fibrosis (scars) along the length of their bile ducts, and eventually this involves the liver itself which can lead to cirrhosis (severe scarring), severe infections (cholangitis), bile duct cancer and death. Although many patients are treated

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of bortezomib in combination with midostaurin and intensive chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML). II. To define the specific toxicities and the dose limiting toxicity (DLT) of midostaurin

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. INDUCTION CHEMOTHERAPY - For patients randomized to receive Idarubicin (Arm I, AI regimen) will be given Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) along with Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3). - For patients randomized to receive

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVES: I. To investigate the association of common single nucleotide polymorphisms (SNPs) and haplotypes of the three multidrug resistance (MDR) genes with treatment outcome in the clinical studies. II. To assess the effect of ATP-binding cassette (ABC) B1, ABCC1, and ABCG2

Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The investigators have demonstrated previously that the calcium channel antagonists (CCAs) verapamil, nifedipine, and diltiazem can block in vitro and in vivo meningioma growth at clinically relevant doses (Jensen, Lee et al. 1995; Jensen, Petr et al. 2000; Jensen and Wurster 2001). However, only

Safety and Efficacy of Iron Reduction by Phlebotomy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background Hematopoietic stem cell transplantation (HSCT) is increasingly used as a treatment for a variety of malignant and non-malignant conditions. With improvements in conditioning regimens and post-transplant care, more HSCT recipients are becoming long-term survivors and therefore increasing

Therapy for Chronic Cold Agglutinin Disease

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Background Chronic cold agglutinin disease (CAD) is mediated by monoclonal cold-reactive autoantibodies that bind to erythrocyte surface antigens, causing haemagglutination and complement-mediated haemolysis. Anaemia is severe (Hb 8.0 g/dL or lower) in one-third of patients and complement-induced

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PRIMARY OBJECTIVE: I. To estimate the proportion of patients with previously-untreated chronic phase chronic myelogenous leukemia (CML) attaining major molecular response by 12 months of treatment with dasatinib. SECONDARY OBJECTIVES: I. To estimate the proportion of patients with Philadelphia

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye